| Trial ID: | L6045 |
| Source ID: | NCT04457050
|
| Associated Drug: |
Sofosbuvir 400 Milligram
|
| Title: |
Effect of Hepatitis C Clearance on Insulin Resistance
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Resistance|Hepatitis C
|
| Interventions: |
DRUG: Sofosbuvir 400 milligram|DRUG: Daclatasvir 60 milligram|DRUG: Ribavirin 400 milligram|DRUG: Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab
|
| Outcome Measures: |
Primary: Change in the insulin resistance before and after hepatitis C clearance, Assess the change in the value of Homeostatic Model Assessment for Insulin resistance (Homeostatic Model Assessment for Insulin Resistance) after hepatitis C treatment by calculating the HOMA-IR for all patients at baseline and the re-calculation at 12 weeks after viral clearance to clarify the impact of hepatitis C treatment by direct antiviral drugs on insulin sensitivity., at baseline and 12 weeks after sustained virologic response | Secondary: Prevalence of insulin resistance among hepatitis C patients, Prevalence of insulin resistance among hepatitis C patients, at baseline|Sustained virologic response, Sustained virologic response, at 12 weeks after treatment
|
| Sponsor/Collaborators: |
Sponsor: Alexandria University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
160
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2017-10-30
|
| Completion Date: |
2019-12-30
|
| Results First Posted: |
|
| Last Update Posted: |
2020-07-07
|
| Locations: |
Faculty of Medicine, Alexandria, 21521, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT04457050
|
